Business Context and Reporting Period
Company: NeuroSense Therapeutics Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: June 2026 (Event date: June 8, 2026)
Principal Office: Herzliya, Israel
The filing reports on a constructive meeting held with Health Canada regarding the regulatory pathway for the Company's product candidate, PrimeC, intended for the treatment of amyotrophic lateral sclerosis (ALS).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory developments and does not contain financial statements.
Material Changes
There are no financial material changes reported. The primary update is the progression of regulatory discussions with Health Canada, where the Company presented additional data to support a potential New Drug Submission (NDS).
Guidance, Outlook, and Management Commentary
- Regulatory Strategy: The Company presented clinical, biomarker, and long-term outcome data to support its proposed NDS strategy for PrimeC in Canada.
- Timeline: An official response from Health Canada is currently expected in the third quarter of 2026.
- Next Steps: The Company will provide further updates on the regulatory process once the official response is received.
Investor Verification Checklist
- Confirm the specific content of the "additional data" presented to Health Canada.
- Monitor for the official response from Health Canada expected in Q3 2026.
- Verify the Company's cash runway given the lack of revenue and the ongoing costs of clinical/regulatory activities.
- Review prior filings for the status of PrimeC in other jurisdictions (e.g., FDA).